| 000 | 06774nam a22004813i 4500 | ||
|---|---|---|---|
| 001 | EBC6424457 | ||
| 003 | MiAaPQ | ||
| 005 | 20240724114752.0 | ||
| 006 | m o d | | ||
| 007 | cr cnu|||||||| | ||
| 008 | 240724s2020 xx o ||||0 eng d | ||
| 020 |
_a9781839160790 _q(electronic bk.) |
||
| 020 | _z9781788018760 | ||
| 035 | _a(MiAaPQ)EBC6424457 | ||
| 035 | _a(Au-PeEL)EBL6424457 | ||
| 035 | _a(OCoLC)1230566745 | ||
| 040 |
_aMiAaPQ _beng _erda _epn _cMiAaPQ _dMiAaPQ |
||
| 050 | 4 | _aRM301.25 .P446 2021 | |
| 082 | 0 | _a615.19 | |
| 100 | 1 | _aIsherwood, Beverley. | |
| 245 | 1 | 0 | _aPhenotypic Drug Discovery. |
| 250 | _a1st ed. | ||
| 264 | 1 |
_aLa Vergne : _bRoyal Society of Chemistry, The, _c2020. |
|
| 264 | 4 | _c©2021. | |
| 300 | _a1 online resource (272 pages) | ||
| 336 |
_atext _btxt _2rdacontent |
||
| 337 |
_acomputer _bc _2rdamedia |
||
| 338 |
_aonline resource _bcr _2rdacarrier |
||
| 490 | 1 | _aIssn Series | |
| 505 | 0 | _aCover -- Preface -- Foreword: Phenotypic Drug Discovery: A Personal Perspective -- PDD Comes of Age -- Managing Risk -- Added Value -- Long-term Innovation -- Closing Remarks -- References -- Contents -- Chapter 1 Phenotypic Drug Discovery: History, Evolution, Future -- 1.1 Introduction -- 1.2 History -- 1.3 Translational Knowledge Gaps -- 1.4 Formalization of Empiricism into PDD -- 1.5 The Future of PDD -- References -- Chapter 2 Development and Validation of Disease Assays for Phenotypic Screening -- 2.1 Introduction -- 2.2 Assay Design: Connecting to Clinically Relevant Biology -- 2.3 Assay Performance: Planning for Analysis -- 2.4 Triage of Phenotypic Hits -- 2.5 Mechanism Classification of Phenotypic Hits -- 2.6 Early Compound De-risking: Human Pharmacology-based Screening Funnel -- 2.7 Challenges and Opportunities: Data Management and Analysis -- 2.8 Summary and Outlook -- Acknowledgements -- References -- Chapter 3 The Development and Use of Protein and Protein-affinity Libraries for Phenotypic Screening -- 3.1 Introduction -- 3.2 Types of Protein/Protein Affinity Tools for Phenotypic Screening -- 3.3 Application of Protein-based Screening -- 3.4 A Case Study Using Secretome-based Screening - Identification of Potential Paracrine Factors that Stimulate Proliferaiton of Cardiac Cells in the Heart -- 3.5 Summary and Outlook -- Acknowledgements -- References -- Chapter 4 CRISPR/Cas-based Functional Genomic Approaches to Phenotypic Screening -- 4.1 Introduction -- 4.2 Phenotypic Screening with CRISPR/Cas -- 4.3 Functional Genomic Big Data Analytics and Artificial Intelligence -- 4.4 Summary and Outlook -- References -- Chapter 5 Contemporary Techniques for Target Deconvolution and Mode of Action Elucidation -- 5.1 Introduction -- 5.2 Affinity-based Approaches -- 5.3 Functional Genomics Approaches -- 5.4 Cellular Profiling Approaches. | |
| 505 | 8 | _a5.5 Knowledge-based and Computational Approaches -- 5.6 Discussion and Outlook -- References -- Chapter 6 Artificial Intelligence as an Enabler for Phenotypic Drug Discovery -- 6.1 Introduction -- 6.2 Data-driven Assay Development -- 6.3 Accelerating Hit Discovery with Iterative Machine Learning -- 6.4 Increasing the Throughput of Screening and Compound Triage -- 6.5 Target Deconvolution and Lead Optimization -- 6.6 Discussion and Outlook -- Abbreviations -- Acknowledgements -- References -- Chapter 7 Public-Private Partnerships to Advance Phenotypic Drug Discovery -- 7.1 Introduction -- 7.2 Collaborate to Advance Knowledge or to Compete? -- 7.3 What Works and What Doesn't in Biomedical PPP? -- 7.4 Rationale for PDD in Industry and Academia -- 7.5 Rationale of PDD PPP and Three Academic Industrial Models -- 7.6 Conclusion/Outlook -- References -- Chapter 8 Identification of a Novel Class of Small Molecules for Spinal Muscular Atrophy Through High-throughput Phenotypic Screening -- 8.1 Introduction -- 8.2 Discovery of SMN2 Splicing Modulators Through Phenotypic Screening -- 8.3 Mechanism of Action Studies -- 8.4 Summary and Implications for Other Diseases -- Acknowledgements -- References -- Chapter 9 Antibody-based Phenotypic Screening - the Discovery of Oleclumab (MEDI9447) -- 9.1 Introduction -- 9.2 Phenotypic Screening Using Combinatorial Antibody Libraries -- 9.3 In vivo Characterisation of PHEN0203 and Validation of CD73 as an Antibody-tractable Target -- 9.4 Discovery of Oleclumab -- 9.5 Testing Oleclumab in the Clinic -- 9.6 Summary and Outlook -- References -- Chapter 10 Use of Phenotypic Screening in Mice in the Development of a Novel Non-D2-ReceptorTargeting Drug for the Treatment of Schizophren -- 10.1 Introduction -- 10.2 The Development of a Novel Drug Treatment of Schizophrenia -- 10.3 Other Programs in Development -- 10.4 Conclusions. | |
| 505 | 8 | _aAcknowledgements -- References -- Chapter 11 Phenotypic Screening for Drug Discovery in Tuberculosis -- 11.1 Tuberculosis Disease -- 11.2 Phenotypic Screening for Tuberculosis -- 11.3 Contribution to Clinical Successes -- 11.4 Summary and Outlook -- Acknowledgements -- References -- Chapter 12 Why an In Vivo Screening Platform Covering Broad Therapeutic Spectrum is an Ideal Tool for Drug Repositioning: Illustrated by Discovery of a Novel Class of Insulin Sensitizers -- 12.1 The Problem That Needs to Be Solved -- 12.2 The Approach That Melior Has Taken to Address the Problem -- 12.3 The MLR-1023 Story -- 12.4 Lessons Learned from 15 Years of In Vivo Phenotypic Screening -- References -- Chapter 13 Phenotypic Screen Leads to Identification of Novel Posttranscriptional Regulation Machinery for HBV -- 13.1 Introduction -- 13.2 Identification of a Small-molecule Inhibitor of HBsAg -- 13.3 Unbiased MOA Studies -- 13.4 Proposal of a Novel Mechanism and Implications of New Targets for HBV Therapeutics -- References -- Subject Index. | |
| 520 | _aPhenotypic drug discovery has been highlighted in the past decade as an important strategy in the discovery of novel medical entities. This book aims to equip researchers with a thought-provoking guide to the application and development of contemporary phenotypic drug discovery for clinical success. | ||
| 588 | _aDescription based on publisher supplied metadata and other sources. | ||
| 590 | _aElectronic reproduction. Ann Arbor, Michigan : ProQuest Ebook Central, 2024. Available via World Wide Web. Access may be limited to ProQuest Ebook Central affiliated libraries. | ||
| 650 | 0 | _aDrug development. | |
| 655 | 4 | _aElectronic books. | |
| 700 | 1 | _aAugustin, Angelique. | |
| 776 | 0 | 8 |
_iPrint version: _aIsherwood, Beverley _tPhenotypic Drug Discovery _dLa Vergne : Royal Society of Chemistry, The,c2020 _z9781788018760 |
| 797 | 2 | _aProQuest (Firm) | |
| 830 | 0 | _aIssn Series | |
| 856 | 4 | 0 |
_uhttps://ebookcentral.proquest.com/lib/orpp/detail.action?docID=6424457 _zClick to View |
| 999 |
_c23171 _d23171 |
||